TOP vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 20, 2026

TOP

34.8
AI Score
VS
HIVE Wins

HIVE

60.8
AI Score

Investment Advisor Scores

TOP

35score
Recommendation
SELL

HIVE

61score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric TOP HIVE Winner
Revenue 1.08M 79.12M HIVE
Net Income -113,433 -142.91M TOP
Net Margin -10.5% -180.6% TOP
ROE -0.3% -33.8% TOP
ROA -0.1% -15.5% TOP
Total Assets 158.41M 924.64M HIVE
Cash 10.41M 208.04M HIVE

Relative Price Performance (Last 90 Days)

TOP 1M: +548.2% · 3M: +1436.9% HIVE 1M: -4.7% · 3M: -21.3%

Current Technical Phase

TOP

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (224.5% over 20 days), RSI 86

RSI (14): 85.6 · Price: $14.13

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.9 · Price: $3.03

Fundamentals Snapshot

Metric TOP HIVE
Market Cap
Forward P/E 0.0 -5.9
Trailing P/E
Revenue (TTM)
Revenue Growth -0.2% 0.7%
Gross Margin 0.6% 0.4%
Operating Margin -0.4% -0.6%
EPS -0.18 -1.54
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.